- Global Pharma News & Resources

Research Article Cite Cleanascite™ on Fatty Acid Influences in Ovarian Cancer Cell Response

Research Article Cite Cleanascite™ on Fatty Acid Influences in Ovarian Cancer Cell Response


MONMOUTH JUNCTION, NJ, September 30, 2021 -- Biotech Support Group reports on a research article describing the simplicity and efficiency of their lipid depletion technology to determine the influence of fatty acids as a source of energy in tumors. The citation is:


Wang, Xueyu, et al. "Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis."  Cancers 13.19 (2021): 4795.

The tumor microenvir-onment is known to influence cancer epigenomics, which plays an essential role in promoting tumor development and metastatic progression. To study this, the researchers used ovarian cancer cells cocultured in omental conditioned medium (OCM), which mimics the ascites microenvironment, and in vivo tumor growth. To examine whether fatty acids in OCM are the main source of energy for tumors, all fatty acids in OCM were first removed by CleanasciteTM Lipid Removal Reagent. The article states “The omental mixture was subsequently added to the cell culture medium supplemented with 1% FBS for 24 h. OCM was filtered and stored at 4 °C prior to the removal of omentum tissues by centrifugation. To selectively remove lipids and cell debris, Cleanascite™ … was employed for OCM according to the manufacturer’s suggestions.” XTT cell viability analysis was performed and showed that the cell growth rate of ES-2 and MES-OV cells was remarkably reduced when cocultured in lipid-depleted OCM. The effective use of Cleanascite™ helped establish that “both miR-33b overexpression and depletion of fatty acids by Cleanascite in OCM significantly impaired ovarian cancer cell migration and invasion.” The article concludes that that miR-33b is significantly silenced by DNA hypermethylation in metastatic ovarian cancer cells, to adapt to a lipid-rich microenvironment. Restoration of miR-33b was shown to impair lipid metabolic activities and reduce the oncogenic properties of ovarian cancer cells by negatively regulating the TAK1/FASN/CPT1A/NF-κB pathway, indicating that targeting this signaling cascade may be a molecular therapeutic choice for ovarian cancer metastatic progression.


“Its very rewarding to see how Cleanascite™ can enhance cancer research associated with the selective removal of fatty acids. Whenever an investigation needs to consider whether lipids influence cell culture response, Cleanascite™ can be used. It is an aqueous suspension product without harmful solvents, or any other non-specific cytotoxic effects. This ultimately helps researchers decide whether or not lipids, or factors interacting with lipids, impart characteristic changes in cells. This article exemplifies such utility.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group


Click to download whitepaper entitled “Cleanascite™ -  Lipid Removal and Cell Response Applications”


Click to visit Cleanascite™ product page and ordering information

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for Covid-19 and cancer patients. For more information, go to                                                    

For Business Development, contact: Matthew Kuruc 732-274-2866,

Editor Details

Last Updated: 06-Oct-2021